Advertisement

Neurological Sciences

, Volume 39, Issue 12, pp 2183–2196 | Cite as

Beneficial effects of Gelsemium-based treatment against paclitaxel-induced painful symptoms

  • Ludivine Vitet
  • Christine Patte-Mensah
  • Naoual Boujedaini
  • Ayikoé-Guy Mensah-Nyagan
  • Laurence Meyer
Original Article
  • 54 Downloads

Abstract

Chemotherapeutic drugs induce various side effects including painful peripheral neuropathy that represents a major concern. The widely used anticancer drug paclitaxel causes neurological side effects such as burning pain, allodynia, and hyperalgesia. Neuroprotective substances that may effectively counteract paclitaxel-induced neuropathic symptoms are needed. Here, we investigated the potential of Gelsemium sempervirens (GS) to counteract paclitaxel-evoked painful neuropathy in rats. Using the von Frey hair and acetone behavioral tests, we investigated the potential of GS centesimal (C) dilutions 3, 5, and 9C to prevent or to correct paclitaxel-induced cold allodynia and mechanical allodynia/hyperalgesia involved in neuropathic pain. We found that a prophylactic or corrective treatment with GS dilutions prevented or suppressed PAC-evoked cold allodynia and mechanical allodynia/hyperalgesia, by reversing to normal, decreased cold thermal and mechanical pain thresholds of PAC-treated rats. In particular, preventive or corrective treatments with GS dilution 3C counteracted PAC-evoked allodynic and hyperalgesic responses. Also, GS dilution 5C (in a lesser extent than 3C) significantly reduced PAC-induced mechanical allodynia/hyperalgesia while GS dilution 9C was ineffective. PAC-evoked neuropathic symptoms were efficiently reduced after 1 week treatment with GS dilutions 3 or 5C and the beneficial action increased after 2 weeks. GS dilutions, particularly 3C, also counteracted or prevented PAC-induced sciatic nerve axon alterations and decreased the density of intraepidermal nerve fibers. Altogether, these results obtained in the rat preclinical model suggest that GS dilution-based treatment may constitute an interesting option to explore for the long-term management of pain without undesirable effects.

Keywords

Chemotherapy-induced painful neuropathy Allodynia Hyperalgesia Therapeutic strategy Gelsemium 

Abbreviations

C

Centesimal

GS

Gelsemium sempervirens

PAC

Paclitaxel

SC

Spinal cord

W

Water

Notes

Acknowledgements

This work was supported by grants from the University of Strasbourg and INSERM.

Funding

The study was granted by the University of Strasbourg and INSERM.

Compliance with ethical standards

Conflict of interest

BOIRON financially supported the project, provided the treatments, but did not take legal responsibility for the study, which was sponsored by the University of Strasbourg and INSERM. NB from BOIRON contributed to the study design but did not participate in the realization of the study or in data analysis and interpretation.

Ethical approval

Animal care and manipulations were performed according to The European Community Council Directives (2010/63/UE) and under the supervision of authorized investigators. All experiments performed minimized the number of animals used and their suffering in accordance with the Alsace Department of Veterinary Public Health Guide for the Care and Use of Laboratory Animals. A national project authorization was delivered by the French Ministry of Higher Education and Research and by CREMEAS a local ethical committee (Project authorization number 9373). The experiments also followed the International Association for the Study of Pain ethical guidelines.

References

  1. 1.
    Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, Authier N (2011) Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 10:407–417CrossRefGoogle Scholar
  2. 2.
    Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9–17CrossRefGoogle Scholar
  3. 3.
    Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155:2461–2470CrossRefGoogle Scholar
  4. 4.
    Miltenburg NC, Boogerd W (2014) Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 40:872–882CrossRefGoogle Scholar
  5. 5.
    Brewer JR, Morrison G, Dolan ME, Fleming GF (2016) Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol 140:176–183CrossRefGoogle Scholar
  6. 6.
    Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, Coudore F, Bourinet E, Eschalier A (2009) Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 6:620–629CrossRefGoogle Scholar
  7. 7.
    Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109:132–142CrossRefGoogle Scholar
  8. 8.
    Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63:1549–1563CrossRefGoogle Scholar
  9. 9.
    Fehrenbacher JC (2015) Chemotherapy-induced peripheral neuropathy. Prog Mol Biol Transl Sci 131:471–508CrossRefGoogle Scholar
  10. 10.
    Cai J, Zheng T, Masood R, Smith DL, Hinton DR, Kim CN, Fang G, Bhalla K, Gill PS (2000) Paclitaxel induces apoptosis in AIDS-related Kaposi’s sarcoma cells. Sarcoma 4:37–45CrossRefGoogle Scholar
  11. 11.
    Croom KF, Dhillon S (2011) Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 71:2213–2229CrossRefGoogle Scholar
  12. 12.
    Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797–1805CrossRefGoogle Scholar
  13. 13.
    Le XF, Bast RC Jr (2011) Src family kinases and paclitaxel sensitivity. Cancer Biol Ther 12:260–269CrossRefGoogle Scholar
  14. 14.
    Singh S, Dash AK (2009) Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. Crit Rev Ther Drug Carrier Syst 26:333–372CrossRefGoogle Scholar
  15. 15.
    Young M, Plosker GL (2001) Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer. Pharmacoeconomics 19:1227–1259CrossRefGoogle Scholar
  16. 16.
    Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, Tredici G (1995) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75:1141–1150CrossRefGoogle Scholar
  17. 17.
    Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35:304–311CrossRefGoogle Scholar
  18. 18.
    Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM (1997) Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neuro-Oncol 35:47–53CrossRefGoogle Scholar
  19. 19.
    Gordon AN, Stringer CA, Matthews CM, Willis DL, Nemunaitis J (1997) Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting. J Clin Oncol 15:1965–1973CrossRefGoogle Scholar
  20. 20.
    Polomano RC, Mannes AJ, Clark US, Bennett GJ (2001) A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94:293–304CrossRefGoogle Scholar
  21. 21.
    Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15Google Scholar
  22. 22.
    van den Bent MJ, van Raaij-van den Aarssen VJ, Verweij J, Doorn PA, and Sillevis Smitt PA (1997) Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve 20:750–752Google Scholar
  23. 23.
    Durand JP, Alexandre J, Guillevin L, Goldwasser F (2005) Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anti-Cancer Drugs 16:587–591CrossRefGoogle Scholar
  24. 24.
    Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055–4061CrossRefGoogle Scholar
  25. 25.
    Lang E, Hord AH, Denson D (1996) Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Pain 68:151–155CrossRefGoogle Scholar
  26. 26.
    Ling B, Authier N, Balayssac D, Eschalier A, Coudore F (2007) Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 128:225–234CrossRefGoogle Scholar
  27. 27.
    Marchand F, Alloui A, Chapuy E, Jourdan D, Pelissier T, Ardid D, Hernandez A, Eschalier A (2003) Evidence for a monoamine mediated, opioid-independent, antihyperalgesic effect of venlafaxine, a non-tricyclic antidepressant, in a neurogenic pain model in rats. Pain 103:229–235CrossRefGoogle Scholar
  28. 28.
    Galie E, Villani V, Terrenato I, Pace A (2017) Tapentadol in neuropathic pain cancer patients: a prospective open label study. Neurol Sci 38:1747–1752CrossRefGoogle Scholar
  29. 29.
    Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG (2010) Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy. Cell Mol Life Sci 67:3017–3034CrossRefGoogle Scholar
  30. 30.
    Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG (2011) Allopregnanolone prevents and suppresses oxaliplatin-evoked painful neuropathy: multi-parametric assessment and direct evidence. Pain 152:170–181CrossRefGoogle Scholar
  31. 31.
    Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG (2013) Neurosteroid 3alpha-androstanediol efficiently counteracts paclitaxel-induced peripheral neuropathy and painful symptoms. PLoS One 8:e80915CrossRefGoogle Scholar
  32. 32.
    Jevtovic-Todorovic V, Covey DF, Todorovic SM (2009) Are neuroactive steroids promising therapeutic agents in the management of acute and chronic pain? Psychoneuroendocrinology 34:S178–S185CrossRefGoogle Scholar
  33. 33.
    Pathirathna S, Brimelow BC, Jagodic MM, Krishnan K, Jiang X, Zorumski CF, Mennerick S, Covey DF, Todorovic SM, Jevtovic-Todorovic V (2005) New evidence that both T-type calcium channels and GABAA channels are responsible for the potent peripheral analgesic effects of 5alpha-reduced neuroactive steroids. Pain 114:429–443CrossRefGoogle Scholar
  34. 34.
    Pathirathna S, Todorovic SM, Covey DF, Jevtovic-Todorovic V (2005) 5alpha-reduced neuroactive steroids alleviate thermal and mechanical hyperalgesia in rats with neuropathic pain. Pain 117:326–339CrossRefGoogle Scholar
  35. 35.
    Patte-Mensah C, Meyer L, Taleb O, Mensah-Nyagan AG (2014) Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain. Prog Neurobiol 113:70–78CrossRefGoogle Scholar
  36. 36.
    Venard C, Boujedaini N, Belon P, Mensah-Nyagan AG, Patte-Mensah C (2008) Regulation of neurosteroid allopregnanolone biosynthesis in the rat spinal cord by glycine and the alkaloidal analogs strychnine and gelsemine. Neuroscience 153:154–161CrossRefGoogle Scholar
  37. 37.
    Venard C, Boujedaini N, Mensah-Nyagan AG, Patte-Mensah C (2011) Comparative analysis of gelsemine and Gelsemium sempervirens activity on neurosteroid allopregnanolone formation in the spinal cord and limbic system. Evid Based Complement Alternat Med 2011:407617Google Scholar
  38. 38.
    Bannerman DM, Rawlins JN, McHugh SB, Deacon RM, Yee BK, Bast T, Zhang WN, Pothuizen HH, Feldon J (2004) Regional dissociations within the hippocampus—memory and anxiety. Neurosci Biobehav Rev 28:273–283CrossRefGoogle Scholar
  39. 39.
    Bremner JD (1999) Alterations in brain structure and function associated with post-traumatic stress disorder. Semin Clin Neuropsychiatry 4:249–255Google Scholar
  40. 40.
    Davis M (1992) The role of the amygdala in fear and anxiety. Annu Rev Neurosci 15:353–375CrossRefGoogle Scholar
  41. 41.
    Haines DE, Mihailoff GA, Yezierski RP (1997) The spinal cord. In: Haines DE (ed) Fundamental neuroscience. Churchill Livingstone Inc., New York, pp 129–141Google Scholar
  42. 42.
    Millan MJ (1999) The induction of pain: an integrative review. Prog Neurobiol 57:1–164CrossRefGoogle Scholar
  43. 43.
    Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355–474CrossRefGoogle Scholar
  44. 44.
    Rauch SL, Shin LM, Wright CI (2003) Neuroimaging studies of amygdala function in anxiety disorders. Ann N Y Acad Sci 985:389–410CrossRefGoogle Scholar
  45. 45.
    Qiu HQ, Xu Y, Jin GL, Yang J, Liu M, Li SP, Yu CX (2015) Koumine enhances spinal cord 3alpha-hydroxysteroid oxidoreductase expression and activity in a rat model of neuropathic pain. Mol Pain 11:46CrossRefGoogle Scholar
  46. 46.
    Wu YE, Li YD, Luo YJ, Wang TX, Wang HJ, Chen SN, Qu WM, Huang ZL (2015) Gelsemine alleviates both neuropathic pain and sleep disturbance in partial sciatic nerve ligation mice. Acta Pharmacol Sin 36:1308–1317CrossRefGoogle Scholar
  47. 47.
    Xu Y, Qiu HQ, Liu H, Liu M, Huang ZY, Yang J, Su YP, Yu CX (2012) Effects of koumine, an alkaloid of Gelsemium elegans Benth., on inflammatory and neuropathic pain models and possible mechanism with allopregnanolone. Pharmacol Biochem Behav 101:504–514CrossRefGoogle Scholar
  48. 48.
    Zhang JY, Gong N, Huang JL, Guo LC, Wang YX (2013) Gelsemine, a principal alkaloid from Gelsemium sempervirens Ait., exhibits potent and specific antinociception in chronic pain by acting at spinal alpha3 glycine receptors. Pain 154:2452–2462CrossRefGoogle Scholar
  49. 49.
    Zhang JY, Wang YX (2015) Gelsemium analgesia and the spinal glycine receptor/allopregnanolone pathway. Fitoterapia 100:35–43CrossRefGoogle Scholar
  50. 50.
    Jouany J, Poitevin B, Saint-Jean Y, Masson JL (2003) Gelsemium sempervirens. In: Boiron (ed) Pharmacologie et Matière Médicale Homéopathique. CEDH, Paris, pp 337–383Google Scholar
  51. 51.
    Meyer L, Venard C, Schaeffer V, Patte-Mensah C, Mensah-Nyagan AG (2008) The biological activity of 3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds after sciatic nerve injury. Neurobiol Dis 30:30–41CrossRefGoogle Scholar
  52. 52.
    Patte-Mensah C, Meyer L, Schaeffer V, Mensah-Nyagan AG (2010) Selective regulation of 3 alpha-hydroxysteroid oxido-reductase expression in dorsal root ganglion neurons: a possible mechanism to cope with peripheral nerve injury-induced chronic pain. Pain 150:522–534CrossRefGoogle Scholar
  53. 53.
    Lauria G, Lombardi R, Borgna M, Penza P, Bianchi R, Savino C, Canta A, Nicolini G, Marmiroli P, Cavaletti G (2005) Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. J Peripher Nerv Syst 10:202–208CrossRefGoogle Scholar
  54. 54.
    Lee MK, Cleveland DW (1996) Neuronal intermediate filaments. Annu Rev Neurosci 19:187–217CrossRefGoogle Scholar
  55. 55.
    Shaw G, Osborn M, Weber K (1986) Reactivity of a panel of neurofilament antibodies on phosphorylated and dephosphorylated neurofilaments. Eur J Cell Biol 42:1–9Google Scholar
  56. 56.
    Siau C, Xiao W, Bennett GJ (2006) Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 201:507–514CrossRefGoogle Scholar
  57. 57.
    Price DD (2000) Psychological and neural mechanisms of the affective dimension of pain. Science 288:1769–1772CrossRefGoogle Scholar
  58. 58.
    Saade NE, Jabbur SJ (2008) Nociceptive behavior in animal models for peripheral neuropathy: spinal and supraspinal mechanisms. Prog Neurobiol 86:22–47CrossRefGoogle Scholar
  59. 59.
    Thompson JM, Neugebauer V (2017) Amygdala plasticity and pain. Pain Res Manag 2017:8296501Google Scholar
  60. 60.
    Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA (2003) Neurosteroid modulation of GABAA receptors. Prog Neurobiol 71:67–80CrossRefGoogle Scholar
  61. 61.
    Chirumbolo S, Bjorklund G (2018) Homeopathic dilutions, Hahnemann principles, and the solvent issue: must we address ethanol as a “homeopathic” or a “chemical” issue? Homeopathy 107:40–44CrossRefGoogle Scholar
  62. 62.
    Finocchi C, Ferrari M (2011) Female reproductive steroids and neuronal excitability. Neurol Sci 32(Suppl 1):S31–S35CrossRefGoogle Scholar
  63. 63.
    Guille C, Spencer S, Cavus I, Epperson CN (2008) The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment. Epilepsy Behav 13:12–24CrossRefGoogle Scholar
  64. 64.
    Patte-Mensah C, Kibaly C, Mensah-Nyagan AG (2005) Substance P inhibits progesterone conversion to neuroactive metabolites in spinal sensory circuit: a potential component of nociception. Proc Natl Acad Sci U S A 102:9044–9049CrossRefGoogle Scholar
  65. 65.
    Patte-Mensah C, Li S, Mensah-Nyagan AG (2004) Impact of neuropathic pain on the gene expression and activity of cytochrome P450side-chain-cleavage in sensory neural networks. Cell Mol Life Sci 61:2274–2284CrossRefGoogle Scholar
  66. 66.
    Patte-Mensah C, Penning TM, Mensah-Nyagan AG (2004) Anatomical and cellular localization of neuroactive 5 alpha/3 alpha-reduced steroid-synthesizing enzymes in the spinal cord. J Comp Neurol 477:286–299CrossRefGoogle Scholar
  67. 67.
    Hwang BY, Kim ES, Kim CH, Kwon JY, Kim HK (2012) Gender differences in paclitaxel-induced neuropathic pain behavior and analgesic response in rats. Korean J Anesthesiol 62:66–72CrossRefGoogle Scholar
  68. 68.
    Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R (2008) Opioid complications and side effects. Pain Physician 11:S105–S120Google Scholar
  69. 69.
    Carter GT, Duong V, Ho S, Ngo KC, Greer CL, Weeks DL (2014) Side effects of commonly prescribed analgesic medications. Phys Med Rehabil Clin N Am 25:457–470CrossRefGoogle Scholar
  70. 70.
    Paris A, Schmidlin S, Mouret S, Hodaj E, Marijnen P, Boujedaini N, Polosan M, Cracowski JL (2012) Effect of Gelsemium 5CH and 15CH on anticipatory anxiety: a phase III, single-centre, randomized, placebo-controlled study. Fundam Clin Pharmacol 26:751–760CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS)Université de StrasbourgStrasbourgFrance
  2. 2.Laboratoires BOIRONSainte-Foy-lès-LyonFrance

Personalised recommendations